Intersection between genetic polymorphisms and immune deviation in type 1 diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 4, 2013, Pages 285-291

  Long, Alice ^a   Buckner, Jane H ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

CD25; genotype; PTPN2; PTPN22; single nucleotide polymorphisms; type 1 diabetes

Indexed keywords

CYTOKINE; INTERLEUKIN 2; PROTEIN TYROSINE PHOSPHATASE;

ALLELE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL TYPE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

DIABETES MELLITUS, TYPE 1; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 84880313934     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32836285b6     Document Type: Review

References (52)

1. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009; 360:1646-1654.
2. Morahan G. Insights into type 1 diabetes provided by genetic analyses. Curr Opin Endocrinol Diabetes Obes 2012; 19:263-270.
3. Pociot F, Akolkar B, Concannon P, et al. Genetics of type 1 diabetes. what's next? Diabetes 2010; 59:1561-1571.
4. Gregersen PK, Lee HS, Batliwalla F, Begovich AB. PTPN22: setting thresholds for autoimmunity. Semin Immunol 2006; 18:214-223.
5. Lavrikova EY, Nikitin AG, Kuraeva TL, et al. The carriage of the type 1 diabetes-associated R262W variant of human LNK correlates with increased proliferation of peripheral blood monocytes in diabetic patients. Pediatr Diabetes 2011; 12:127-132.
6. Wiede F, Shields BJ, Chew SH, et al. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J Clin Invest 2011; 121:4758-4774.
7. Shinoda K, Tokoyoda K, Hanazawa A, et al. Type II membrane protein CD69 regulates the formation of resting T-helper memory. Proc Natl Acad Sci USA 2012; 109:7409-7414.
8. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009.
9. Dendrou CA, Plagnol V, Fung E, et al. Cell-specific protein phenotypesforthe autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009; 41:1011-1015.
10. Gregersen PK. Closing the gap between genotype and phenotype. Nat Genet 2009; 41:958-959.
11. Rieck M, Arechiga A, Onengut-Gumuscu S, et al. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007; 179:4704-4710.
12. Bradfield JP, Qu HQ, Wang K, et al. A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. PLoS Genet 2011; 7:e1002293.
13. Velaga MR, Wilson V, Jennings CE, et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 2004; 89:5862-5865.
14. Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75:330-337.
15. Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75:504-507.
16. Canton I, Akhtar S, Gavalas NG, et al. A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Genes Immun 2005; 6:584-587.
17. Vandiedonck C, Capdevielle C, Giraud M, et al. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 2006; 59:404-407.
18. Begovich AB, Caillier SJ, Alexander HC, et al. The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis. Am J Hum Genet 2005; 76:184-187.
19. Martin MC, Oliver J, Urcelay E, et al. The functional genetic variation in the PTPN22 gene has a negligible effect on the susceptibility to develop inflammatory bowel disease. Tissue Antigens 2005; 66:314-317.
20. Wipff J, Allanore Y, Kahan A, et al. Lack of association between the protein tyrosine phosphatase nonreceptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population. Ann Rheum Dis 2006; 65:1230-1232.
21. Vang T, Liu WH, Delacroix L, et al. LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol 2012; 8:437-446.
22. Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37:1317-1319.
23. Dai X, James R, Habib T, et al. The PTPN22 risk variant promotes systemic autoimmunity in murine models. J Clin Invest 2013; 123:2024-2036.
24. Arechiga A, Habib T, He Y, et al. The PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 2009; 182:3343-3347.
25. Menard L, Saadoun D, Isnardi I, et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Investig 2011; 121:3635-3644.
26. Habib T, Funk A, Rieck M, et al. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol 2012; 188:487-496.
27. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38:13-25.
28. Hulme MA, Wasserfall CH, Atkinson MA, Brusko TM. Central role for inter-leukin-2 in type 1 diabetes. Diabetes 2012; 61:14-22.
29. Welcome Trust Case Control Consortium. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared, controls. Nature 2007; 447:661-678.
30. Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010; 466:113-117.
31. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39:857-864.
32. International Multliple Sclerosis Genetics Consortuim. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357:851-862.
33. Brand OJ, Lowe CE, Heward JM, et al. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf) 2007; 66:508-512.
34. Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010; 362:1686-1697.
35. Maier LM, Lowe CE, Cooper J, et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 2009; 5:e1000322.
36. Matesanz F, Caro-Maldonado A, Fedetz M, et al. IL2RA/CD25 polymorphisms contribute to multiple sclerosis susceptibility. J Neurol 2007; 254:682-684.
37. Franke A, Balschun T, Karlsen TH, et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008; 40:713-715.
38. van Heel DA, Franke L, Hunt KA, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Geanet 2007; 39:827-829.
39. Garg G, Tyler JR, Yang JH, et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4\+CD25\+ regulatory T cell function. J Immunol 2012; 188:4644-4653.
40. Qu HQ, Verlaan DJ, Ge B, et al. A cis-acting regulatory variant in the IL2RA locus. J Immunol 2009; 183:5158-5162.
41. Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007; 9:1074-1082.
42. Butter F, Davison L, Viturawong T, et al. Proteome-wide analysis of disease-associated SNPs that show allele-specific transcription factor binding. PLoS Genet 2012; 8:e1002982.
43. Brusko TM, Wasserfall CH, Hulme MA, et al. Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PLoS ONE 2009; 4:e7980.
44. Russell SE, Moore AC, Fallon PG, Walsh PT. Soluble IL-2Ralpha (sCD25) exacerbates autoimmunity and enhances the developmentof Th17 responses in mice. PLoS ONE 2012; 7:e47748.
45. Maier LM, Anderson DE, Severson CA, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009; 182:1541-1547.
46. Long SA, Cerosaletti K, Wan JY, et al. An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(\+) T cells. Genes Immun 2011; 12:116-125.
47. Bourdeau A, Dube N, Tremblay ML. Cytoplasmic protein tyrosine phospha-tases, regulation and function: the roles of PTP1B and TC-PTP. Curr Opin Cell Biol 2005; 17:203-209.
48. Doody KM, Bourdeau A, Tremblay ML. T-cell proteintyrosine phosphataseis a key regulator in immune cell signaling: lessons from the knockout mouse model and implicationsin human disease. Immunol Rev 2009; 228:325-341.
49. Buckner JH. Mechanisms of impaired regulation by CD4(\+)CD25 (\+)FOXP3(\+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10:849-859.
50. Yamanouchi J, Rainbow D, Serra P, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 2007; 39:329-337.
51. Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008; 28:687-697.
52. Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4\+CD25\+ regulatory T cells of type 1 diabetic subjects. Diabetes 2010; 59:407-415.